Edmundo Rivera, MD
Psychiatry · Orange City, FLNPI 1437231115
Payments from drug & device makers
Across 591 payments — averaging $81.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$12K
- AbbVie$9K
- Idorsia Pharmaceuticals US Inc$8K
- Sunovion Pharmaceuticals Inc.$5K
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $9K from 23 others
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$28,09058%
- Travel & lodging$1,1642%
- Food & beverage$18,48538%
- Education$2070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 43 | $11,931 |
| AbbVie(2 entities) | 139 | $9,271 |
| Idorsia Pharmaceuticals US Inc | 18 | $7,647 |
| Sunovion Pharmaceuticals Inc. | 11 | $4,817 |
| Teva Pharmaceuticals USA, Inc. | 36 | $2,617 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 71 | $2,369 |
| Otsuka America Pharmaceutical, Inc. | 48 | $2,010 |
| Johnson & Johnson | 31 | $1,102 |
| Neurocrine Biosciences, Inc. | 23 | $859 |
| Vanda Pharmaceuticals Inc. | 24 | $832 |
| Axsome Therapeutics, Inc. | 14 | $806 |
| Jazz Pharmaceuticals Inc. | 21 | $770 |
| Neuronetics, Inc. | 20 | $725 |
| E.r. Squibb & Sons, L.L.C. | 13 | $645 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $321 |
| Lundbeck LLC | 13 | $307 |
| Bausch Health US, LLC | 14 | $290 |
| Livanova USA, Inc. | 2 | $145 |
| Tris Pharma Inc | 1 | $124 |
| Almatica Pharma LLC | 5 | $121 |
| Indivior Inc. | 4 | $69 |
| Corium, LLC | 2 | $62 |
| Supernus Pharmaceuticals, Inc. | 2 | $50 |
| Merck | 2 | $40 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| TMS Neurohealth Centers Inc. | 1 | $39 |
| Eisai Inc. | 2 | $32 |
| Shire North American Group Inc | 1 | $30 |
| Harmony Biosciences LLC | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$43,391
- ARISTADA INITIO$10,848
- VRAYLAR$7,381
- QUVIVIQ$7,316
- LATUDA$4,623
- LYBALVI$1,406
- AUSTEDO$1,332
- CAPLYTA$950
- Austedo XR$591
- COBENFY$477
- ABILIFY MAINTENA$466
- REXULTI$464
- INGREZZA$442
- XYWAV$394
- Fanapt$375
- Auvelity$360
- SPRAVATO$242
- VIIBRYD$200
- XYREM$150
- INVEGA SUSTENNA$134
How this compares
$48,097 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $139,279 |
| VraylarCariprazine Hcl | 20 | $50,923 |
| CaplytaLumateperone Tosylate | 25 | $40,029 |
| TrintellixVortioxetine Hydrobromide | 40 | $21,694 |
| FanaptIloperidone | 12 | $15,059 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $12,655 |
| BelsomraSuvorexant | 28 | $12,368 |
| XanaxAlprazolam | 11 | $12,277 |
| Lisdexamfetamine Dimesylate | 34 | $6,819 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 34 | $3,697 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 48 | $3,556 |
| Aripiprazole | 56 | $3,519 |
| Alprazolam | 281 | $2,721 |
| Lurasidone Hcl | 18 | $2,143 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 82 | $2,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,617 | $139,27913 claims |
| AbbVieVraylar | $9,271 | $50,92320 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,369 | $40,02925 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $321 | $21,69440 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $832 | $15,05912 claims |
| Axsome Therapeutics, Inc.Auvelity | $806 | $12,65511 claims |
| MerckBelsomra | $40 | $12,36828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Orange City
- Adly ThebaudOrange City$1.5M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.